Takaaki Kondo

Takaaki Kondo is currently the General Manager of the Gene and Cell Therapy R&D group at Ajinomoto Co., Inc. since March 2024, after serving as a Manager/Senior Researcher at the company's Bioscience & Fine Chemicals Research Institute. Prior to this role, Takaaki Kondo held a managerial position at Mitsubishi Chemical Group's Corporate Venture Capital from July 2022 to February 2024 and also served as a Manager at Mitsubishi Chemical Holdings Corporation from April 2021 to June 2022. Takaaki Kondo's extensive experience includes managing alliances for drug discovery projects at Mitsubishi Tanabe Pharma Corporation, focusing on neurology, autoimmune, and inflammatory diseases from October 2018 to March 2021, as well as previous roles as a Senior and Research Scientist and Postdoctoral Fellow at Harvard Medical School and Brigham and Women's Hospital. Takaaki Kondo holds a Ph.D. in Immunology and Infectious Diseases from Kumamoto University, completed between 2005 and 2008.